Evaluation of short-term prognosis of OFS combined with AI in the treatment of premenopausal breast cancer
Objective To analyze the clinical value of combination of ovarian function inhibition and aromatase inhibitor in the treatment of premenopausal young breast cancer.Method 60 premenopausal breast cancer patients admitted to our hospital from April 2020 to October 2021 were selected as research object.According to different treatment schemes,the patients were divided into experi-mental group and control group,with 30 cases in each group;The control group was treated with tamoxifen,and the experimental group was treated with ovarian function inhibition combined with aromatase inhibitor.The therapeutic effects of the two groups were com-pared.Results The incidence of adverse reactions such as osteoporosis,arthralgia,irregular vaginal bleeding and gastrointestinal reac-tions in the experimental group was lower than that in the control group(P<0.05).Six months after the end of chemotherapy,the o-varian function recovery rate of patients in the experimental group was 93.33%,which was higher than 73.33%of the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the recovery rate of ovarian function between the two groups 12 months after chemotherapy(P>0.05).The incidence of ovarian cyst and endometrial thickening of patients in the experimental group after 6 and 12 months of chemotherapy were lower than those in the control group(P<0.05).There was no statistically significant difference between the two groups after 3 months of chemotherapy(P>0.05).Conclusion The short-term effect of ovarian function inhibition combined with aromatase inhibitor in the treatment of premenopausal breast cancer is better than that of tamoxifen alone,which is worthy of clinical reference.
Premenopausal breast cancerOvarian function inhibitionAromatase inhibitorTamoxifen
万方数据
维普
